Plasma tau and neurodegenerative markers as predictors of rate of AD progression

项目摘要： 阿尔茨海默氏病和相关痴呆症 (ADRD) 影响着全世界数以千万计的人， 对患者、家庭和医疗保健系统来说是一个巨大的挑战。对于一些出席的人 对于轻度认知障碍，认知和功能会迅速恶化，而对于其他人来说， 进展速度可能不存在或慢得多。了解进展率的这种变异性是 对于患者、家庭和临床研究人员来说至关重要，并且常见的情况无法很好地预测， 临床可用的生物标志物工具。 AD 病理学和神经退行性变的血液标记物 由于其非侵入性、成本低，有可能在临床研究甚至临床护理中广泛使用 相对于神经影像学，并且缺乏限制其使用的医学禁忌症。在这里我们检查一组 新开发的基于血液的 AD 生物标志物（包括神经丝轻链、磷酸化 tau 物种、tau、 和抗体片段）可能会填补这一空白。利用从大型诊所前瞻性获取的样本 人口和当地临床研究，我们将确定这些血浆测量与 “现实世界”认知和功能下降的可变速率，以及基于成像的测量 神经变性和 AD 病理进展。

Project Abstract: Alzheimer's disease and related dementias (ADRD) affect tens of millions of people around the world and represent a staggering challenge for patients, families, and healthcare systems. For some who present with mild levels of cognitive impairment, there is rapid worsening of cognition and function, whereas for others, the rate of progression can be absent or much slower. Understanding this variability in rate of progression is critically important to patients, families, and clinical researchers alike, and is not well-predicted by common, clinically available biomarker tools. Blood-based markers of AD pathology and neurodegeneration have potential for widespread use in clinical research and even clinical care, due to their non-invasiveness, cost relative to neuroimaging, and lack of medical contraindications to limit their use. Here we examine a set of newly developed, blood-based AD biomarkers (including neurofilament light chain, phospho-tau species, tau, and Ab fragments) that may fill this gap. Leveraging prospectively acquired samples from a large clinic population and from local clinical research studies, we will determine how these plasma measures relate to variable rates of "real-world" cognitive and functional decline, as well as to imaging-based measures of neurodegeneration and AD pathologic progression.